Work

Rapid Response, Unexpected Risk: A ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Case with Lazarus Syndrome and Fatal Thrombosis

Year: 2026

Type: article

Abstract: A 57-year-old woman with a ROS1-rearranged NSCLC patient demonstrated a Lazarus response to crizotinib but later developed recurrent pulmonary embolism (PE) with right ventricular (RV) failure. This incident highlights the potential crizotinib-related thrombotic risk and the need for appropriate monitoring of vascular complications, particularly in limited-option settings such as Thailand.

Source: Asian Medical Journal and Alternative Medicine

DOI: 10.70933/2773-9465.1331

Authors: Piraya Patrathiranond, Sasipim Thitvirachawat, Panuch Eiamprapaporn

Institutions: Thammasat University Hospital, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W7153229013

FWCI:

Cites:

Cited by:

Related to: